Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
89Zr-DFO-xiRA63
- Development stage
- Preclinical
- Lead developer
- Commissariat à l’Énergie Atomique et aux Énergies Alternatives
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Administration
- Intravenous
01
Overview
89Zr-DFO-xiRA63 is a zirconium-89 (89Zr)-labeled chimeric monoclonal antibody conjugate developed by the French Alternative Energies and Atomic Energy Commission (CEA) for immuno-positron emission tomography (immunoPET) imaging. It consists of the chimeric monoclonal antibody xiRA63 (chimeric Rendomab A63), which specifically targets the endothelin receptor type A (ETA), conjugated to the chelator desferrioxamine (DFO) and radiolabeled with the positron emitter 89Zr. The agent is designed to cross the blood-brain tumor barrier (BBTB) and target ETA-positive glioblastoma stem cells, enabling non-invasive detection, characterization, and stratification of glioblastoma.
- Other names
- 89Zr-labeled chimeric Rendomab A6389Zr-xiRA63[89Zr]Zr-DFO-xiRA63[89Zr]Zr-xiRA63zirconium-89-labeled chimeric Rendomab A63zirconium89-labeled chimeric Rendomab A63zirconium 89-labeled chimeric Rendomab A63
02
Targets
EDNRA (Endothelin receptor type A)
Beyond the preview
Go deeper on 89Zr-DFO-xiRA63.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 89Zr-DFO-xiRA63.